Summary The vaso-active drug hydralazine causes a considerable increase in the cytotoxic effect of melphalan towards the KHT tumour in mice. The enhancement in response, measured as the concentration of melphalan required to achieve a given tumour response, is 3.0 and 2.35 when determined using the regrowth delay assay and the technique for determining surviving fraction in vitro following treatment in vivo respectively. In contrast, measurement of systemic toxicity shows that the addition of hydralazine only causes a small increase (ER= 1.15) in melphalan damage. This suggests that the drug combination may have some therapeutic benefit. The tumour specificity for the action of hydralazine is supported by the finding that binding of 3H-misonidazole is increased in tumours but not in other tissues when mice are treated with hydralazine. Increased binding of labelled misonidazole is associated with an increase in the level and duration of hypoxia, which will occur as a consequence of changes in tumour blood flow brought about by hydralazine. However, hypoxia per se is not responsible for the enhanced effect of melphalan, since the agent BW12C, which also induces substantial tumour hypoxia as a result of changing the 02 affinity of haemoglobin, has no effect on melphalan tumour cytotoxicity.
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There have been various reports showing that vasoactive drugs can significantly affect the nature of blood flow in both experimental rodent and human tumours (Algire & Lagallais, 1951; Cater et al., 1962; Kruuv et al., 1967; Vorhees & Babbs, 1982 ; Knapp et al., 1985) . Reduced blood flow in tumours can cause lowering of the oxygen status of the tumour, thereby causing radiation resistance (Kruuv et al., 1967) . This so-called 'stealing' effect has recently been exploited by Chaplin and Acker (1987) in order to increase the anti-tumour effect of the bio-reductive agent, RSU 1069 (Adams et al., 1984 ) a compound which is activated under hypoxic conditions to give a species 100 x more toxic than the parent compound (Stratford et al., 1986) .
Reduction of blood flow in tumours may also be potentially useful for enhancing the effects of some anti-cancer drugs. The rationale for this is that, administration of the vaso-active drug at the time at which the chemotherapeutic agent has reached its maximum tumour concentration, will inhibit loss of active drug from the tumour. This could increase the overall exposure of the tumour cells to the cytotoxic drug. This paper describes the results of a study of the effect of the vasoactive agent hydralazine on the cytotoxic action of melphalan (L-phenylalanine mustard, L-PAM) towards the KHT sarcoma in mice.
Materials and methods
Mice and tumours Eight to 12 week old male Category IV C3H/He mice, obtained from NIMR, Mill Hill, London in 1984 and subsequently bred 'in-house', were used in the present experiments. The KHT sarcoma (Kallman et al., 1967) , provided by Dr P. Twentyman, MRC, Cambridge in 1983, was maintained by inoculation of a tumour brei into the gastrocnemius muscle of female mice. Generally, tumours required for experimentation were derived by subcutaneous injection of 105 to 5 x 105 viable tumour cells (obtained by trypsin/ DNAase digestion) in the mid-dorsal pelvic region of the back. Mice were treated when tumours attained a mean diameter of 6-8mm.
Cell survival assay The response of the KHT sarcoma to therapy was measured using an in vivo to in vitro assay (Thomson & Rauth, 1974 (Courtenay, 1983 Binding of 3H-misonidazole to tumour and normal tissues The method of Garrecht and Chapman (1983) was used to assess the efficiency of binding of misonidazole in hypoxic tissue. Tritiated misonidazole (relative specific activity 236 ,uCi mg-1) was prepared from 1-(2-carboxy-3-methoxy propyl)-2-nitroimidazole by reduction with tritiated sodium borohydride (relative specific activity 5-10 Ci M -obtained from Amersham International plc) following the procedure of Born and Smith (1983) . The product was diluted with unlabelled misonidazole to a relative specific activity of 30 1Ci mg-1 and each mouse in the distribution study received 250 mg kg-I i.p. of this product.
The total tritium content of weighed samples (0.05 to 0.2 g) of tumour and normal tissues was measured 24 h after the injection of misonidazole, by digestion with 1.0 ml of Solusol (National Diagnostic Ltd) at 60°C for 24 h. After digestion, 3.0 ml ethanol and 15.0 ml scintillant (6.5 g 1 PPO 0.5 g 1-1 POPOP in toluene) were added and the samples were counted on a Packard Tricarb liquid scintillation counter. A set of variably quenched standards were used for calibration. These were prepared by adding a known activity of tritiated water to a set of 8 samples containing between zero and 0.2ml of whole blood digested as above. Any very highly coloured samples were bleached by incubation at 60°C for 2h with benzoyl peroxide (0.4ml, 5% w/v in toluene) before the addition of ethanol and scintillant.
Three groups of 5 male C3H mice bearing the KHT tumour were injected with tritium-labelled misonidazole (250mgkg-1). Group 1 received misonidazole only, group 2 received in i.v. injection of hydralazine (5.0mgkg-1) 15 minutes after the misonidazole and group 3 recieved 3 injections of hydralazine at 90 min intervals starting 15 min after the misonidazole. All animals were autopsied 24h after the injection of misonidazole and tritium analysis carried out immediately thereafter.
Systemic toxicity
Non-tumour bearing C3H male mice were injected with different concentrations of melphalan 15min prior to treatment with hydralazine. 
Results
Tumour response Data given in Figure I show the response of KHT tumour cells taken from mice given various doses of melphalan with or without treatment with 5mg kg-1 hydralazine 15 min later. The numbers of tumours used to determine each point are indicated, together with standard errors of the pooled survival determinations. It is clear that post treatment of mice with hydralazine substantially increases the anti-tumour effect of melphalan. The enhancement ratio (ER) is 2.35 and is equal to the ratio of the slopes derived from regression lines fitted through a surviving fraction of I at zero melphalan dose. At a dose of 5mgkg-1 hydralazine alone has no effect on survival of KHT tumour cells. Figure 2 shows the effect of different doses of hydralazine administered i.v. 15 min after treatment of mice with 6mgkg-1 melphalan. The enhancing effect of hydralazine in decreasing cell survival reaches a maximum value over the dose range 5-15mgkg-1. However, even at the low dose of 1 mg kg-1, hydralazine can cause a significant increase in cell killing relative to melphalan alone, reducing the surviving fraction from 9.6x10-2 to 3.7x10-2.
The enhancing effect of hydralazine (5 mg kg 1) on tumour cell survival is critically dependent upon the time of administration relative to that of melphalan. This is shown in Figure 3 . Clearly, there is significant enhancement of cytotoxicity when hydralazine is given from 90 min before to 90 min after melphalan. The greatest effect appearing to occur when hydralazine is given 15 min after melphalan. This corresponds with the time at which melphalan has reached its peak plasma levels in C3H mice (Lee & Workman, 1986) .
Hydralazine causes induction of almost 100% hypoxia in the KHT tumour and this lasts for about 90 min (Stratford et al., 1988) . Experiments have been carried out to determine to what extent the induction of hypoxia is responsible for the observed potentiation of melphalan toxicity. This was investigated using the agent BW12C, a drug which greatly increases tumour hypoxia by increasing the oxygen affinity of haemoglobin (Adams et al., 1986) . Experiments were carried out to compare the effects of BW12C and hydralazine in the KHT tumour. Mice were treated with a single i.v.
dose of BW12C (70mgkg-1) 15min after administration of melphalan. The dose of BW12C induces close to 100% tumour hypoxia within minutes after administration (Adams et al., 1986) and the influence of this treatment on surviving fraction of tumour cells is given in Table I . Clearly, BW12C has no effect on the cytotoxic effect of melphalan, indicating therefore that induction of hypoxia per se is unlikely to be responsible for the potentiating effect of hydralazine. Table I also shows results of experiments in which mice were given melphalan followed 15min later by occlusion of the tumour blood supply by a physical clamp kept in place for 1 h. Application of a clamp alone to the tumour for this time causes no measurable cell killing, however, when given after melphalan, substantial cytotoxicity is observed. The enhancement brought about by clamping is similar to that seen with hydralazine.
Data from experiments designed to investigate any effect of hydralazine treatment on the efficiency of any repair of cellular damage caused by melphalan are also recorded in Table I . Normally, tumours are excised and cell suspensions prepared for plating in vitro 24 h after treatment with drugs. During this time repair of potentially lethal damage may occur (see e.g. Little et al., 1973 , McNally & Sheldon, 1977 . In order to investigate whether hydralazine could be affect- Hydralazine after (hours) Figure 3 The effect on tumour cell survival of giving hydralazine (5 mg kg-1) i.v. to mice at varying times before or after melphalan (6mg kg-'). Symbols + s.e. are surviving fractions derived from separate determinations on at least three tumours. ing such a repair process, tumours from treated mice were excised 6h after treatment and tumour cell survival compared with that obtained when excision was at 24h. Results given in Table I show that hydralazine induced enhancement of cell killing is no different at 6 h from that at 24 h. This suggests that inhibition of repair processes is unlikely to contribute to the observed effect.
All the experiments so far described were carried out with subcutaneous tumours. Substantial differences in blood flow may occur in tumours implanted in alternative sites. Therefore, the effect of hydralazine on the toxicity of melphalan was evaluated in mice with the KHT tumour implanted into the gastrocnemius muscle. Table I Figure 4 shows mean values of growth delay for treated tumours (T) relative to untreated controls (Tc); plotted as a function of melphalan dose. Clearly, hydralazine when combined with melphalan, causes an increase in growth delay compared to that for melphalan alone. An ER of 3.0 was derived from linear regression lines fitted through the origin at zero melphalan dose. The value of ER derived using the growth delay data is close to that calculated from the results obtained by the clonogenic assay in vitro. Treatments wth hydralazine alone has no effect on growth of KHT tumours.
Therapeutic gain
The systemic toxicity of treatment with the drug combination was compared to that for melphalan alone. This was carried out in order to investigate whether any grounds existed for an increase in therapeutic benefit using this combined drug treatment. Lethal doses (LD50) were measured at either 7 or 90 days. These times were chosen to reflect relative toxicities in dose-limiting tissues i.e. gut and bone marrow respectively. Table III shows that there is a small increase in toxicity with the drug combination. However, the enhancement is substantially less than the ER observed for the tumour response.
Binding of 3H-misonidazole It is known that the radiosensitizer and bioreductive drug, misonidazole, is bound in vivo to oxygen deficient tissue (Garrecht & Chapman, 1983) . Binding studies with isotopically labelled misonidazole offer an indirect method for determining the influence of hydralazine on blood flow, which will reflect itself as a change in oxygenation, in various tissues. The reductive process(es) leading to binding are inhibited by oxygen, therefore the efficiency of binding is a measure of the degree of hypoxia (van Os-Corby & Chapman, 1986) . Mice were treated with tritiatedmisonidazole with and without hydralazine as described previously and measurements of binding of label to various Figure 5 Binding of 3H-misonidazole to various tissues in C3H mice bearing the KHT tumour. A, misonidazole alone; B, misonidazole followed by hydralazine 15min later; C, as for B but with two additional doses of hydralazine given at 90 min intervals thereafter. aSignificantly different from a ratio of 1.0 at P< 10-4.
mouse tissues are given in the histogram in Figure 5 . In all treatment groups, significantly greater binding of labelled material was observed in the KHT tumour, the liver and the spleen compared to that in blood or cerebellum. For the group treated with misonidazole alone there is little difference between the tumour, liver and spleen. However, administration of single or multiple doses of hydralazine increases the amount of label in the tumour but not in any of the other tissues (Table IV) (Table IV) . 3. Hydralazine, occlusion of the blood supply and treatment with BW12C all greatly increase the degree of hypoxia in the KHT tumour. However, BW12C does not enhance the anti-tumour action of melphalan, strongly suggesting that the degree of tumour hypoxia is not a factor in tumour sensitivity to melphalan.
Hydralazine is used in the treatment of acute hypertension. It acts mainly on the vascular smooth muscle causing peripheral vaso-dilation and decreased arterial blood pressure. It is known that hydralazine reduces but does not completely occlude blood flow in some experimental tumours (Cater et al., 1962; Kruuv et al., 1967; Vorhees & Babbs, 1982; Chan et al., 1984; Chaplin & Acker, 1987) . The data in Figure 3 show that hydralazine is effective in causing enhancement even when given before treatment with melphalan. This could be explained on the basis that hydralazine does not prevent the access of melphalan in the tumours but reduces the rate of tumour clearance. This would increase therefore the overall exposure of tumour cells to melphalan. A minor but possibly significant factor that may contribute to the enhancing effect of hydralazine may be a reduction in tumour pH caused by the reduced blood flow, increased hypoxia and retention of acid products of anaerobic metabolism. A small decrease in extracellular pH could increase the stability of melphalan (Ross, 1962) thereby leading to increased effectiveness of this drug.
Several studies have shown enhancement of the antitumour effect of melphalen in vivo by a variety of agents. Among these misonidazole, benznidazole and other nitroimidazoles can act as 'chemopotentiators'. The mechanism of the effect has its basis in bioreductive activation of the nitro compound causing damage that is only expressed when cells are exposed to a second cytotoxic treatment (Siemann, 1984) . Changes in melphalan pharmacokinetics is also thought to be important (Lee & Workman, 1986) as well as changes in tumour vascular function (Murray et al., 1987) . The anaesthetic, safan, can increase the effectiveness of melphalan in the B16 melanoma but this is accompanied by an equivalent increase in normal tissue toxicity (Peacock & Stephens, 1978) . Similarly, the vaso-dilating agent, verapamil, also increases the cytotoxicity of melphalan in some experimental tumours and some normal tissues (Robinson et al., 1985) . In this latter study it was shown that the effect of verapamil is to change melphalan pharmacokinetics and cellular uptake rather than causing any alterations in tumour blood flow (Robinson et al., 1985 (Robinson et al., , 1986 .
The evidence from the work reported here indicates that hydralazine has a high degree of specificity in enhancing the anti-tumour effect of melphalan. If hydralazine, or other blood flow modifiers do not increase melphalan toxicity in dose-limiting human normal tissues, they could have a r6le to play in cancer chemotherapy, in addition to any use in combination with bioreductive rad;osensitizing drugs (Chaplin & Acker, 1987; Brown 1987; Stratford et al., 1987) .
